Modification of Mecp2 dosage alters axonal transport through the Huntingtin/Hap1 pathway

Neurobiology of Disease

Volumn 45, Issue 2, 2012, Pages 786-795

  Roux, Jean Christophe ^a,b   Zala, Diana ^c,d,e   Panayotis, Nicolas ^a,b   Borges Correia, Ana ^a,b   Saudou, Frédéric ^c,d,e   Villard, Laurent ^a,b  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT CURIE   (France)

^d CNRS   (France)

^e INSERM U1005   (France)

Author keywords

App; Axonal trafficking; Bdnf; Mecp2; Rett syndrome

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CARRIER PROTEIN; HUNTINGTIN; HUNTINGTIN ASSOCIATED PROTEIN 1; MERCAPTAMINE; METHYL CPG BINDING PROTEIN 2; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; GENE; GENE DOSAGE; GENE EXPRESSION; HAP1 GENE; HUNTINGTIN GENE; IN VITRO STUDY; IN VIVO STUDY; LIFESPAN; MALE; MECP2 GENE; MOTOR DYSFUNCTION; MOUSE; NERVE FIBER TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN SECRETION; PROTEIN TRANSPORT; RAT; RETT SYNDROME; STRIATE CORTEX;

ANIMALS; AXONAL TRANSPORT; BLOTTING, WESTERN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; MALE; METHYL-CPG-BINDING PROTEIN 2; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN TRANSPORT; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RETT SYNDROME; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84855816126     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.11.002     Document Type: Article

References (66)

1. Aber K.M., et al. Methyl-CpG-binding protein 2 is localized in the postsynaptic compartment: an immunochemical study of subcellular fractions. Neuroscience 2003, 116:77-80.
2. Abuhatzira L., et al. MeCP2 deficiency in the brain decreases BDNF levels by REST/CoREST-mediated repression and increases TRKB production. Epigenetics 2007, 2:214-222.
3. Abuhatzira, L., et al., 2009. MeCP2 involvement in the regulation of neuronal alpha-tubulin production. Hum. Mol. Genet. 15, 18 (8), 1415-1423.
4. Altar C.A., DiStefano P.S. Neurotrophin trafficking by anterograde transport. Trends Neurosci. 1998, 21:433-437.
5. Altar C.A., et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997, 389:856-860.
6. Baquet Z.C., et al. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J. Neurosci. 2004, 24:4250-4258.
7. Borrell-Pages M., et al. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell. Mol. Life Sci. 2006, 63:2642-2660.
8. Bracaglia G., et al. Methyl-CpG-binding protein 2 is phosphorylated by homeodomain-interacting protein kinase 2 and contributes to apoptosis. EMBO Rep. 2009, 10:1327-1333.
9. Calfa G., et al. Experimental models of Rett syndrome based on Mecp2 dysfunction. Exp. Biol. Med. (Maywood) 2011, 236:3-19.
10. Caviston J.P., Holzbaur E.L. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol. 2009, 19:147-155.
11. Chahrour M., Zoghbi H.Y. The story of Rett syndrome: from clinic to neurobiology. Neuron 2007, 56:422-437.
12. Chahrour M., et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008, 320:1224-1229.
13. Chan E.Y., et al. Targeted disruption of Huntingtin-associated protein-1 (Hap1) results in postnatal death due to depressed feeding behavior. Hum. Mol. Genet. 2002, 11:945-959.
14. Chang Q., et al. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 2006, 49:341-348.
15. Chen W.G., et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 2003, 302:885-889.
16. Colin E., et al. Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J. 2008, 27:2124-2134.
17. Dragatsis I., et al. Huntingtin-associated protein 1 (Hap1) mutant mice bypassing the early postnatal lethality are neuroanatomically normal and fertile but display growth retardation. Hum. Mol. Genet. 2004, 13:3115-3125.
18. Fujinaga R., et al. Neuroanatomical distribution of Huntingtin-associated protein 1-mRNA in the male mouse brain. J. Comp. Neurol. 2004, 478:88-109.
19. Gauthier L.R., et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118:127-138.
20. Geranton S.M., et al. A role for transcriptional repressor methyl-CpG-binding protein 2 and plasticity-related gene serum- and glucocorticoid-inducible kinase 1 in the induction of inflammatory pain states. J. Neurosci. 2007, 27:6163-6173.
21. Gibrat C., Cicchetti F. Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:380-389.
22. Greenberg M.E., et al. New insights in the biology of BDNF synthesis and release: implications in CNS function. J. Neurosci. 2009, 29:12764-12767.
23. Grillner S., et al. Mechanisms for selection of basic motor programs-roles for the striatum and pallidum. Trends Neurosci. 2005, 28:364-370.
24. Guy J., et al. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 2001, 27:322-326.
25. Huang E.J., Reichardt L.F. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 2001, 24:677-736.
26. Jones P.L., et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 1998, 19:187-191.
27. Kotliarova S., et al. Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fluorescent aggregates. J. Neurochem. 2005, 93:641-653.
28. Lesort M., et al. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. 2003, 278:3825-3830.
29. Lewis J.D., et al. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 1992, 69:905-914.
30. Long S.W., et al. A brain-derived MeCP2 complex supports a role for MeCP2 in RNA processing. Biosci. Rep. 2010, 31:333-343.
31. Lu B., et al. The yin and yang of neurotrophin action. Nat. Rev. Neurosci. 2005, 6:603-614.
32. Mari F., et al. CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. Hum. Mol. Genet. 2005, 14:1935-1946.
33. Markham A., et al. BDNF increases rat brain mitochondrial respiratory coupling at complex I, but not complex II. Eur. J. Neurosci. 2004, 20:1189-1196.
34. Martinowich K., et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 2003, 302:890-893.
35. McConoughey S.J., et al. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol. Med. 2010, 2:349-370.
36. McGuire J.R., et al. Interaction of Huntingtin-associated protein-1 with kinesin light chain: implications in intracellular trafficking in neurons. J. Biol. Chem. 2006, 281:3552-3559.
37. Meehan R.R., et al. Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res. 1992, 20:5085-5092.
38. Menalled L.B., et al. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J. Neurosci. 2002, 22:8266-8276.
39. Miyake K., Nagai K. Phosphorylation of methyl-CpG binding protein 2 (MeCP2) regulates the intracellular localization during neuronal cell differentiation. Neurochem. Int. 2007, 50:264-270.
40. Mnatzakanian G.N., et al. A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nat. Genet. 2004, 36:339-341.
41. Munsie L., et al. Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease. Hum. Mol. Genet. 2011, 20:1937-1951.
42. Nan X., et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393:386-389.
43. Nuber U.A., et al. Up-regulation of glucocorticoid-regulated genes in a mouse model of Rett syndrome. Hum. Mol. Genet. 2005, 14:2247-2256.
44. Ogier M., et al. Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. J. Neurosci. 2007, 27:10912-10917.
45. Oo T.F., et al. Brain-derived neurotrophic factor regulates early postnatal developmental cell death of dopamine neurons of the substantia nigra in vivo. Mol. Cell. Neurosci. 2009, 41:440-447.
46. Panayotis N., et al. Morphological and functional alterations in the substantia nigra pars compacta of the Mecp2-null mouse. Neurobiol. Dis. 2011, 41:385-397.
47. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Brain Res. Rev. 1995, 20:91-127.
48. Paxinos G., Franklin P. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego.
49. Poo M.M. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2001, 2:24-32.
50. Pratte M., et al. Progressive motor and respiratory metabolism deficits in post-weaning Mecp2-null male mice. Behav. Brain Res. 2011, 216:313-320.
51. Rangone H., et al. The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur. J. Neurosci. 2004, 19:273-279.
52. Ricceri L., et al. Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches. Behav. Pharmacol. 2008, 19:501-517.
53. Samaco R.C., et al. Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:21966-21971.
54. Sheng G., et al. Hypothalamic huntingtin-associated protein 1 as a mediator of feeding behavior. Nat. Med. 2006, 12:526-533.
55. Skene P.J., et al. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol. Cell 2010, 37:457-468.
56. Sun Y.E., Wu H. The ups and downs of BDNF in Rett syndrome. Neuron 2006, 49:321-323.
57. Tang T.S., et al. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 2003, 39:227-239.
58. Tropea D., et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2029-2034.
59. Van Esch H., et al. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am. J. Hum. Genet. 2005, 77:442-453.
60. Viemari J.C., et al. Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice. J. Neurosci. 2005, 25:11521-11530.
61. Wang H., et al. Dysregulation of brain-derived neurotrophic factor expression and neurosecretory function in Mecp2 null mice. J. Neurosci. 2006, 26:10911-10915.
62. Xie Y., et al. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J. Neurosci. 2010, 30:14708-14718.
63. Young J.I., et al. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17551-17558.
64. Zala D., et al. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum. Mol. Genet. 2008, 17:3837-3846.
65. Zhou Z., et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 2006, 52:255-269.
66. Zuccato C., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.